Genprex Inc Stock Price, News & Analysis

Genprex (NASDAQ: GNPX) announced on November 19, 2025 that it added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of Reqorsa gene therapy (quaratusugene ozeplasmid) in lung cancer.

The company noted the Acclaim trials are supported by FDA Fast Track designation and said it expects to add additional sites over the coming months to expand patient access and expedite enrollment.

Genprex (NASDAQ: GNPX) announced the USPTO granted a U.S. patent covering use of its lead candidate Reqorsa gene therapy in combination with PD-L1 antibodies (example: Tecentriq) for cancer treatment, with protection through 2037. The patent is said to apply to Genprex's Acclaim-3 clinical trial in small cell lung cancer and is already granted in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel, which the company says would extend protection to those trials if granted.

Genprex (NASDAQ: GNPX) announced that the European Patent Office has communicated its intent to grant a patent for the use of Reqorsa gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer (Nov 4, 2025).

This expands Genprex's patent estate that already includes granted patents for the same combination in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Reqorsa is being developed alongside approved cancer drugs for lung cancer, with preclinical data showing complementarity with targeted drugs and immunotherapies.

The release cites EU and global lung cancer burden: ~250,000 EU deaths in 2021, 11.9% of new cancer diagnoses in EU-27 (2020), and GLOBOCAN 2022 estimates of ~2.48M new global cases and ~1.8M deaths.

Genprex (NASDAQ: GNPX) announced a registered direct offering of 377,780 shares at $9.00 per share for gross proceeds of about $3.4 million, priced at-the-market under Nasdaq rules. In a concurrent private placement, Genprex will issue unregistered short-term warrants to buy up to 755,560 shares at $8.75 per share, exercisable immediately and expiring 24 months after effectiveness of a resale registration statement, which could generate up to $6.6 million if fully exercised.

The offering is expected to close on or about October 29, 2025, H.C. Wainwright & Co. is placement agent, and net proceeds are intended for working capital and general corporate purposes. No assurance warrants will be exercised.

Genprex (NASDAQ: GNPX) announced collaborators presented positive preclinical data for Reqorsa® (quaratusugene ozeplasmid) at the 2025 AACR-NCI-EORTC conference (Oct 22–26, 2025).

University of Michigan data showed REQORSA upregulated TUSC2 in EML4-ALK+ NSCLC cell lines and patient-derived organoids, induced apoptosis including in alectinib-resistant cells, and that combining REQORSA with the ALK inhibitor alectinib increased apoptosis and improved survival in a human ALK+-EML4 mouse xenograft model.

The poster was presented Oct 25, 2025 and is available on the company website.

Genprex (NASDAQ:GNPX) announced a registered direct offering of 243,622 common shares at $11.21 per share for expected gross proceeds of approximately $2.7 million, priced at-the-market under Nasdaq rules.

In a concurrent private placement the company will issue unregistered short-term warrants to purchase up to 487,244 shares at an $11.00 exercise price, exercisable upon issuance and expiring 24 months after effectiveness of a resale registration statement; full exercise would generate up to $5.4 million additional gross proceeds. H.C. Wainwright & Co. is the exclusive placement agent. Proceeds are intended for working capital and general corporate purposes.

Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa® (quaratusugene ozeplasmid) at the 2025 AACR‑NCI‑EROTC conference in Boston on October 25, 2025. Studies show QO upregulates TUSC2 and induces apoptosis in ALK‑EML4 positive NSCLC models.

Key findings: QO alone and combined with alectinib reduced tumor volume by 79% in an NCI‑H2228 mouse model versus 60% for alectinib alone; QO increased caspase 3/7 activity, pro‑apoptotic markers, DNA fragmentation, and reduced colony formation. Results support a potential clinical trial pathway for REQORSA in ALK+ NSCLC.

Genprex (NASDAQ: GNPX) said collaborators will present positive preclinical data for Reqorsa® gene therapy (quaratusugene ozeplasmid) for ALK-EML4 positive non-small cell lung cancer at the 2025 AACR-NCI-EROTC conference in Boston.

The poster from the University of Michigan Rogel Cancer Center will be shown on October 25, 2025 (12:30–4:00 p.m. ET) and reports TUSC2 upregulation by Reqorsa inducing apoptosis in EML4-ALK bearing NSCLC in preclinical studies. Genprex cited a Sponsored Research Agreement from October 2024 with the University of Michigan and noted co-sponsorship by patient group ALK Positive. Laboratory data reported tumor-cell uptake of TUSC2 after Reqorsa treatment at 10–33x versus normal cells.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announced its participation in three major conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10), the King Faisal Specialist Hospital & C3 Davos Healthcare Summit (September 8), and the Investor Summit Group Q3 Virtual Conference (September 16-17).

President and CEO Ryan Confer will deliver presentations highlighting Genprex's gene therapies for cancer and diabetes. Management will be available for one-on-one meetings with investors and conference participants at all events.